Literature DB >> 19028483

Correlation of expression levels of BLyS and its receptors with multiple myeloma.

Shaoqing Ju1, Yueguo Wang, Hongbing Ni, Xudong Wang, Pu Jiang, Xiantao Kong, Renqian Zhong.   

Abstract

OBJECTIVES: To measure the expression levels of B-lymphocyte stimulator (BLyS) and its receptors in multiple myeloma (MM), and to investigate the relationship between them. DESIGN AND METHODS: BLyS and its receptors mRNA levels from peripheral blood mononuclear cells (PBMCs) of 31 MM patients and 30 healthy controls were determined by real-time PCR. The results were presented as the ratios of target genes, to beta(2)-microglobulin (beta(2)M), mRNA. BLyS serum level was determined by enzyme-linked immunosorbent assay (ELISA).
RESULTS: The circulating levels of BLyS in 31 MM patients were significantly elevated and correlated with the levels of Lactate dehydrogenase (LDH). More importantly, 93.55% (29/31) and 90.32% (28/31) of these MM patients had significantly higher expression levels of BLyS and BCMA mRNA respectively, which are correlated with the levels of LDH, while 64.52% (20/31) of these MM patients had significantly lower expression levels of TACI mRNA.
CONCLUSION: BLyS protein concentration and BLyS, TACI and BAFF-R mRNA expression levels were significantly elevated in patients with MM, suggesting that BLyS, TACI and BAFF-R may be involved in the pathogenesis of MM, and that expression levels could serve as a biomarker of prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028483     DOI: 10.1016/j.clinbiochem.2008.10.024

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

1.  Evaluation of the Abelson gene as a control gene for real-time quantitative PCR in multiple myeloma.

Authors:  Yao Zhang; Guo-Rui Ruan
Journal:  Clin Exp Med       Date:  2013-08-30       Impact factor: 3.984

2.  Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.

Authors:  Xianjuan Shen; Yuehua Guo; Jing Qi; Wei Shi; Xinhua Wu; Hongbing Ni; Shaoqing Ju
Journal:  Pathol Oncol Res       Date:  2015-12-21       Impact factor: 3.201

3.  Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.

Authors:  Paul J Maglione; Huaibin M Ko; Minami Tokuyama; Gavin Gyimesi; Camilia Soof; Mingjie Li; Eric Sanchez; Haiming Chen; Lin Radigan; James Berenson; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2019-08-17

4.  TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells.

Authors:  Xinfeng Wang; Jingjing Wang; Hong Liu; Ruirong Xu; Runsheng Ding; Shenhua Jiang; Xudong Wang; Hongming Huang
Journal:  Med Oncol       Date:  2015-09-03       Impact factor: 3.064

Review 5.  B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

Authors:  P J Hengeveld; M J Kersten
Journal:  Blood Cancer J       Date:  2015-02-27       Impact factor: 11.037

6.  The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer.

Authors:  Marilena Kampa; George Notas; Efstathios N Stathopoulos; Andreas Tsapis; Elias Castanas
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

7.  Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Authors:  Molly Went; Amit Sud; Asta Försti; Britt-Marie Halvarsson; Niels Weinhold; Scott Kimber; Mark van Duin; Gudmar Thorleifsson; Amy Holroyd; David C Johnson; Ni Li; Giulia Orlando; Philip J Law; Mina Ali; Bowang Chen; Jonathan S Mitchell; Daniel F Gudbjartsson; Rowan Kuiper; Owen W Stephens; Uta Bertsch; Peter Broderick; Chiara Campo; Obul R Bandapalli; Hermann Einsele; Walter A Gregory; Urban Gullberg; Jens Hillengass; Per Hoffmann; Graham H Jackson; Karl-Heinz Jöckel; Ellinor Johnsson; Sigurður Y Kristinsson; Ulf-Henrik Mellqvist; Hareth Nahi; Douglas Easton; Paul Pharoah; Alison Dunning; Julian Peto; Federico Canzian; Anthony Swerdlow; Rosalind A Eeles; ZSofia Kote-Jarai; Kenneth Muir; Nora Pashayan; Jolanta Nickel; Markus M Nöthen; Thorunn Rafnar; Fiona M Ross; Miguel Inacio da Silva Filho; Hauke Thomsen; Ingemar Turesson; Annette Vangsted; Niels Frost Andersen; Anders Waage; Brian A Walker; Anna-Karin Wihlborg; Annemiek Broyl; Faith E Davies; Unnur Thorsteinsdottir; Christian Langer; Markus Hansson; Hartmut Goldschmidt; Martin Kaiser; Pieter Sonneveld; Kari Stefansson; Gareth J Morgan; Kari Hemminki; Björn Nilsson; Richard S Houlston
Journal:  Nat Commun       Date:  2018-09-13       Impact factor: 14.919

8.  Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.

Authors:  De-Xiu Bu; Reshma Singh; Eugene E Choi; Marco Ruella; Selene Nunez-Cruz; Keith G Mansfield; Paul Bennett; Nathanial Barton; Qilong Wu; Jiquan Zhang; Yongqiang Wang; Lai Wei; Shawn Cogan; Tucker Ezell; Shree Joshi; Kellie J Latimer; Brian Granda; William R Tschantz; Regina M Young; Heather A Huet; Celeste J Richardson; Michael C Milone
Journal:  Oncotarget       Date:  2018-05-25

9.  Possible interplay between estrogen and the BAFF may modify thyroid activity in Graves' disease.

Authors:  Chao-Wen Cheng; Wen-Fang Fang; Kam-Tsun Tang; Jiunn-Diann Lin
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.